Substituted lactams as inhibitors of Aβ protein production
    2.
    发明授权
    Substituted lactams as inhibitors of Aβ protein production 失效
    取代的内酰胺作为Abeta蛋白质生产的抑制剂

    公开(公告)号:US07498324B2

    公开(公告)日:2009-03-03

    申请号:US11788708

    申请日:2007-04-19

    IPC分类号: C07D243/12 A61K31/55

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病,例如阿尔茨海默病和唐氏综合征。

    Substituted lactams as inhibitors of Aβ protein production
    3.
    发明授权
    Substituted lactams as inhibitors of Aβ protein production 有权
    取代的内酰胺作为Abeta蛋白质生产的抑制剂

    公开(公告)号:US07655647B2

    公开(公告)日:2010-02-02

    申请号:US12388944

    申请日:2009-02-19

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病,例如阿尔茨海默病和唐氏综合征。

    Substituted lactams as inhibitors of abeta protein production
    4.
    发明申请
    Substituted lactams as inhibitors of abeta protein production 失效
    取代的内酰胺作为abeta蛋白质生产的抑制剂

    公开(公告)号:US20080221087A1

    公开(公告)日:2008-09-11

    申请号:US11788708

    申请日:2007-04-19

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病,例如阿尔茨海默病和唐氏综合征。

    Substituted lactams as inhibitors of Aβ protein production
    5.
    发明授权
    Substituted lactams as inhibitors of Aβ protein production 有权
    取代的内酰胺作为Abeta蛋白质生产的抑制剂

    公开(公告)号:US07390802B2

    公开(公告)日:2008-06-24

    申请号:US11655637

    申请日:2007-01-19

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病,例如阿尔茨海默病和唐氏综合征。

    SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION
    7.
    发明申请
    SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION 审中-公开
    作为ABETA蛋白质生产的抑制剂的替代的LACTAMS

    公开(公告)号:US20100048541A1

    公开(公告)日:2010-02-25

    申请号:US12561420

    申请日:2009-09-17

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ的生成,从而起到防止淀粉样蛋白的神经沉积的形成的作用。 更具体地说,本发明涉及与阿尔茨海默病和唐氏综合征等淀粉样蛋白生成相关的神经障碍的治疗。

    SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION
    8.
    发明申请
    SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION 审中-公开
    作为蛋白质生产的抑制剂的替代的LACTAMS

    公开(公告)号:US20100069373A1

    公开(公告)日:2010-03-18

    申请号:US12615799

    申请日:2009-11-10

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ的生成,从而起到防止淀粉样蛋白的神经沉积的形成的作用。 更具体地说,本发明涉及与阿尔茨海默病和唐氏综合征等淀粉样蛋白生成相关的神经障碍的治疗。

    SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION
    9.
    发明申请
    SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION 审中-公开
    作为ABETA蛋白质生产的抑制剂的替代的LACTAMS

    公开(公告)号:US20100009966A1

    公开(公告)日:2010-01-14

    申请号:US12560213

    申请日:2009-09-15

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病,例如阿尔茨海默病和唐氏综合征。

    Substituted lactams as inhibitors of A&bgr; protein production
    10.
    发明授权
    Substituted lactams as inhibitors of A&bgr; protein production 有权
    取代的内酰胺作为Abeta蛋白质生产的抑制剂

    公开(公告)号:US06632812B2

    公开(公告)日:2003-10-14

    申请号:US09832455

    申请日:2001-04-11

    IPC分类号: C07D24324

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经障碍,例如阿尔茨海默病和唐氏综合征。